Nonetheless, the most recently published phase II trial of pembrolizumab in recurrent, advanced osteosarcoma patients, did not meet its primary endpoint of achieving disease control at 18 weeks of treatment, inducing solely one metabolic response in a patient with high PD-L1 expression (>50%) [15]. The gene discussed is CD274; the disease is osteosarcoma.